News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
845,160 Results
Type
Article (77430)
Company Profile (726)
Press Release (766983)
Multimedia
Podcasts (195)
Webinars (29)
Section
Business (228600)
Career Advice (3800)
Deals (39363)
Drug Delivery (152)
Drug Development (89777)
Employer Resources (205)
FDA (18164)
Job Trends (17220)
News (389737)
Policy (39046)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3020)
Academic (2)
Accelerated approval (37)
Adcomms (36)
Allergies (156)
Alliances (56309)
ALS (184)
Alzheimer's disease (1818)
Antibody-drug conjugate (ADC) (362)
Approvals (18351)
Artificial intelligence (618)
Autoimmune disease (183)
Automation (43)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (209)
Biotechnology (450)
Bladder cancer (167)
Brain cancer (67)
Breast cancer (684)
Cancer (5190)
Cardiovascular disease (461)
Career advice (3258)
Career pathing (42)
CAR-T (315)
CDC (64)
Celiac Disease (2)
Cell therapy (849)
Cervical cancer (38)
Clinical research (75952)
Collaboration (1897)
Company closure (5)
Compensation (1211)
Complete response letters (78)
COVID-19 (2999)
CRISPR (105)
C-suite (937)
Cystic fibrosis (155)
Data (6491)
Decentralized trials (2)
Denatured (72)
Depression (158)
Diabetes (545)
Diagnostics (7280)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (298)
Drug pricing (226)
Drug shortages (36)
Duchenne muscular dystrophy (249)
Earnings (97930)
Editorial (68)
Employer branding (25)
Employer resources (174)
Events (134479)
Executive appointments (1059)
FDA (21452)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1596)
Gene editing (225)
Generative AI (63)
Gene therapy (688)
GLP-1 (1146)
Government (5441)
Grass and pollen (8)
Guidances (388)
Healthcare (20953)
HIV (69)
Huntington's disease (51)
IgA nephropathy (89)
Immunology and inflammation (306)
Immuno-oncology (70)
Indications (119)
Infectious disease (3307)
Inflammatory bowel disease (215)
Inflation Reduction Act (17)
Influenza (129)
Intellectual property (263)
Interviews (746)
IPO (17860)
IRA (61)
Job creations (4986)
Job search strategy (2633)
JPM (71)
Kidney cancer (17)
Labor market (97)
Layoffs (657)
Leadership (42)
Legal (9973)
Liver cancer (99)
Longevity (16)
Lung cancer (702)
Lymphoma (393)
Machine learning (44)
Management (66)
Manufacturing (888)
MASH (179)
Medical device (15048)
Medtech (15108)
Mergers & acquisitions (22597)
Metabolic disorders (1442)
Multiple sclerosis (174)
NASH (23)
Neurodegenerative disease (372)
Neuropsychiatric disorders (107)
Neuroscience (3196)
Neurotech (1)
NextGen: Class of 2026 (7659)
Non-profit (5120)
Now hiring (69)
Obesity (704)
Opinion (343)
Ovarian cancer (172)
Pain (220)
Pancreatic cancer (243)
Parkinson's disease (307)
Partnered (37)
Patents (534)
Patient recruitment (523)
Peanut (62)
People (65911)
Pharmaceutical (134)
Pharmacy benefit managers (33)
Phase 1 (23488)
Phase 2 (33091)
Phase 3 (24951)
Pipeline (5622)
Policy (348)
Postmarket research (3282)
Preclinical (10368)
Press Release (72)
Prostate cancer (256)
Psychedelics (60)
Radiopharmaceuticals (309)
Rare diseases (962)
Real estate (7212)
Recruiting (81)
Regulatory (28515)
Reports (69)
Research institute (2734)
Resumes & cover letters (592)
Rett syndrome (28)
RNA editing (21)
RSV (90)
Schizophrenia (162)
Series A (265)
Series B (205)
Service/supplier (27)
Sickle cell disease (106)
Special edition (28)
Spinal muscular atrophy (177)
Sponsored (49)
Startups (4238)
State (2)
Stomach cancer (21)
Supply chain (115)
Tariffs (101)
The Weekly (121)
Vaccines (1181)
Venture capital (101)
Weight loss (482)
Women's health (97)
Worklife (22)
Date
Last 7 days (620)
Last 30 days (2465)
Last 365 days (32202)
2026 (4350)
2025 (32661)
2024 (37920)
2023 (42566)
2022 (53928)
2021 (58722)
2020 (57665)
2019 (51315)
2018 (39096)
2017 (36855)
2016 (37798)
2015 (43821)
2014 (38560)
2013 (34695)
2012 (36547)
2011 (36602)
2010 (36146)
Location
Africa (1218)
Alabama (93)
Alaska (7)
Arizona (329)
Arkansas (14)
Asia (50042)
Australia (8588)
California (11899)
Canada (3406)
China (1205)
Colorado (504)
Connecticut (517)
Delaware (357)
Europe (114210)
Florida (1763)
Georgia (384)
Hawaii (4)
Idaho (67)
Illinois (977)
India (76)
Indiana (561)
Iowa (24)
Japan (454)
Kansas (134)
Kentucky (45)
Louisiana (30)
Maine (84)
Maryland (1486)
Massachusetts (8732)
Michigan (365)
Minnesota (676)
Mississippi (6)
Missouri (143)
Montana (36)
Nebraska (29)
Nevada (128)
New Hampshire (87)
New Jersey (3193)
New Mexico (33)
New York (3140)
North Carolina (1646)
North Dakota (10)
Northern California (5737)
Ohio (363)
Oklahoma (23)
Oregon (53)
Pennsylvania (2374)
Puerto Rico (25)
Rhode Island (51)
South America (1584)
South Carolina (69)
South Dakota (1)
Southern California (4603)
Tennessee (182)
Texas (1859)
United States (42795)
Utah (358)
Vermont (1)
Virginia (298)
Washington D.C. (88)
Washington State (993)
West Virginia (4)
Wisconsin (135)
Wyoming (2)
845,160 Results for "karl storz gmbh and co kg".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KGKARL STORZ to provide up to $20 million in bridge financing
Asensus Surgical, Inc. announced that it has entered into a non-binding letter of intent with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company to engage in diligence and negotiations regarding the terms of a potential transaction whereby KARL STORZ may acquire Asensus.
April 3, 2024
·
9 min read
Press Releases
AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)
June 19, 2025
·
3 min read
Deals
Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ
Asensus Surgical, Inc. today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with KARL STORZ Endoscopy-America, Inc.
June 7, 2024
·
7 min read
Biotech Beach
KARL STORZ Launches CollaboratOR 3D for Apple Vision Pro
Pioneering MedTech company KARL STORZ is proud to announce the release of the CollaboratOR 3D app for Apple Vision Pro.
March 7, 2024
·
4 min read
Deals
KARL STORZ Acquires British AI Specialist Innersight Labs
The family-owned MedTech company KARL STORZ announces the acquisition of innovative software manufacturer Innersight Labs Ltd., headquartered in London.
January 10, 2024
·
4 min read
Press Releases
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
February 17, 2026
·
6 min read
Press Releases
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
February 2, 2026
·
9 min read
Business
KARL STORZ unifies its US organizations under a central management team, Sonal Matai named US President
KARL STORZ announced it will centralize management of its United States organizations, including its research and development, manufacturing, and commercial operations, to bring more innovative products to market worldwide with greater speed.
February 6, 2024
·
2 min read
Press Releases
Asensus Surgical Announces Closing of Acquisition by KARL STORZ
August 23, 2024
·
4 min read
Press Releases
Model Medicines to Present Evidence of First Direct-Acting Antiviral Potent Against HCV, HBV, HDV, and Co-Infections at CROI 2026
Over 300 million patients are infected with HCV, HBV, HDV, and their co-infections. MDL-001 is the first oral small molecule to demonstrate potent, direct-acting antiviral activity across all three viruses and their co-infections.
February 18, 2026
·
1 min read
1 of 84,516
Next
